Trial Profile
Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Sep 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Filanesib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Acronyms POMDEFIL
- 27 Apr 2020 Status changed from active, no longer recruiting to completed.
- 22 May 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Results (n=33) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology